Antibody Drug Conjugates (ADCs) are a class of biomolecules that has seen rapid growth with multiple new commercial products. Adoption of single-use (SU) systems has been slow due to concerns about the safe handling of organic solvents and the toxic small molecule payload. Recent advances in single-use technology have overcome these concerns and now provide an understanding of the suitability, scalability, and fluid compatibility of both the single-use components as well as the supporting hardware and controls. In this webinar, we show how single-use technology can deliver consistent and scalable ADC chemistry and functionality with desired final product specifications and high yield.
In this webinar, you will learn:
Director Process and Analytical Development
Lisa joined Merck in January 2010 as an analytical project lead, responsible for ADCs. She brings with her more than 25 years of experience in both organic synthesis and analytical sciences and has had the opportunity to contribute to many projects ranging from discovery to full development, but none has been as exciting as the emergence of ADCs. She also has an extensive chromatography background with experience in integrated LC/MS screening systems.
Principal Production Scientist
As a principal production scientist, Gary is closely involved with the training, transfer, and manufacture of multiple clinical and commercial ADC programs. He has more than 22 years of manufacturing experience, including crude extraction, cell culture, cell banking, purification, and conjugation operations. Gary earned his bachelor’s degree in bacteriology from the University of Wisconsin at Madison.